CELL INTELLIGENCE · 肿瘤细胞治疗研究

免疫检查点敲除筛选揭示 TIGIT-CD155 相互作用是急性髓系白血病中适配体 CAR-T 细胞功能的重要调节因子

Immune checkpoint knockout screen reveals TIGIT-CD155 interaction as a significant modulator of adapter CAR-T cell function in acute myeloid leukemia.

装载靶向组织蛋白酶 G 的双 HLA 限制性 TCR 的 T 细胞可有效根除 AML

T cells dressed up with a dual HLA-restricted TCR targeting cathepsin G drive effective AML eradication.

下一代巨噬细胞工程在癌症治疗中的应用：从 TAM 重编程到 CAR-巨噬细胞

Next-generation macrophage engineering in cancer therapy: From TAM reprogramming to CAR-macrophages.

克服卵巢癌治疗耐药：从分子机制到新兴治疗策略

Overcoming Therapy Resistance in Ovarian Cancer: From Molecular Mechanisms to Emerging Therapeutic Strategies.

NCCRP1 缺失可克服肺腺癌的免疫逃逸

Loss of NCCRP1 overcomes immune evasion in lung adenocarcinoma.

我们的研究结果突显了靶向 NCCRP1 作为一种有前景的治疗策略，可重编程免疫抑制微环境并克服肺腺癌的“冷肿瘤”表型。

T 细胞中 Cblb 基因编辑在慢性抗原刺激下维持扩增与免疫原性 CAR-T 肿瘤杀伤

Cblb Gene Editing in T Cells Sustains Expansion and Immunogenic CAR T Tumor Killing Under Chronic Antigenic Stimulation.

γδ T 细胞活化中的脂质代谢：对卵巢癌免疫治疗的意义

Lipid metabolism in γδ T-cell activation: Implications for immunotherapy in ovarian cancer.

溶瘤病毒治疗抵消免疫治疗后 IFN 无应答癌细胞的选择，但受限于去分化癌细胞的出现

Oncolytic virotherapy counteracts the selection of IFN-unresponsive cancer cells post-immunotherapy but is limited by the emergence of dedifferentiate

恢复软组织肉瘤中 STING 的表达可增强 TIL（肿瘤浸润淋巴细胞）的活化和功能

Restoring STING expression in soft tissue sarcoma increases activation and function of tumor-infiltrating lymphocytes.

通过双重打击规避卵巢癌中 IFN-γ 诱导的耐药：敲除表达 PRAME-TCR 的 NK 细胞的 NKG2A

Circumventing IFN-γ induced resistance in ovarian cancer with a double-hit: NKG2A knockout of PRAME-TCR expressing NK cells.

这种双靶向策略通过同时靶向 HLA 阳性和 HLA 阴性的肿瘤细胞，提供了一种独特优势，促进促炎环境，并增强基于 TCR 的免疫疗法对卵巢癌及其他实体瘤的疗效。